Form 8-K - Current report:
SEC Accession No. 0001104659-24-084952
Filing Date
2024-08-01
Accepted
2024-08-01 16:42:09
Documents
20
Period of Report
2024-07-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2420683d1_8k.htm   iXBRL 8-K 38986
2 EXHIBIT 1.1 tm2420683d1_ex1-1.htm EX-1.1 48887
3 EXHIBIT 4.1 tm2420683d1_ex4-1.htm EX-4.1 87410
4 EXHIBIT 4.2 tm2420683d1_ex4-2.htm EX-4.2 91268
5 EXHIBIT 5.1 tm2420683d1_ex5-1.htm EX-5.1 12053
6 EXHIBIT 10.1 tm2420683d1_ex10-1.htm EX-10.1 217826
7 EXHIBIT 99.1 tm2420683d1_ex99-1.htm EX-99.1 9679
11 GRAPHIC tm2420683d1_ex5-1img001.jpg GRAPHIC 6627
  Complete submission text file 0001104659-24-084952.txt   814895

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA sls-20240730.xsd EX-101.SCH 3042
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20240730_lab.xml EX-101.LAB 34240
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20240730_pre.xml EX-101.PRE 22378
22 EXTRACTED XBRL INSTANCE DOCUMENT tm2420683d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 241167425
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)